Phase 2 study demonstrates improved progression-free survival with Polatuzumab Vedotin in aggressive B-cell lymphomas, indicating potential benefits for high-risk patients.
Key Points
This study aims to evaluate the safety and efficacy of Pola-R-EDCH in high-risk aggressive B-cell lymphomas.
Enrolled patients aged 18-65 with newly diagnosed aggressive B-cell lymphoma
Administered six 21-day cycles of Pola-R-EDCH treatment
Assessed response rates, progression-free survival, and adverse events
100% overall response rate and 81.3% complete response rate
1-year progression-free survival rate estimated at 62.5%
Adverse events included grade ≥3 neutropenia in 93.8% of patients